Laurus Labs CEO on Indian Opportunities

The transcript discusses the company's progress towards achieving a billion-dollar sales target, highlighting the impact of the US economic slowdown and global crisis on their business. It addresses price pressures in the RV APIs and formulations, and how the company is adapting its revenue sources. The challenges of rising raw material costs and supply chain issues are also covered. The company is investing in disruptive technologies and exploring acquisitions to fuel growth. Finally, the transcript touches on the reliance on Chinese imports for APIs and the need for coexistence in the industry.

What is the company's sales target for the financial year 2023?

• 2 billion dollars

• 750 million dollars

• 1 billion dollars

• 500 million dollars

How much of the company's generic sales come from North America?

• 5%

• 10%

• 2%

• 15%

What is the company's target EBITDA margin despite challenges?

• 35%

• 20%

• 25%

• 30%

What percentage of revenue was previously dependent on RV APIs?

• 70-80%

• 60-70%

• 30-40%

• 50-60%

What is the company's strategy for bringing therapies to emerging markets?

• Offering therapies at $30,000 instead of $400,000

• Providing free treatments

• Partnering with local hospitals

• Reducing costs to $50,000 per treatment

What is the company's view on industry coexistence?

• Complete independence is essential

• Only exports are necessary

• Coexistence is essential for progress

• Reliance on imports should be eliminated

How long does the company estimate it will take for India to become self-reliant in APIs?

• 10 years

• 20 years

• 5 years

• 15 years